ClinicalTrials.gg

Warts clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 172 studies for Warts across more than 10 countries. 36 are recruiting or about to start. 154 of them are mainly about Warts (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Condylomata Acuminata too: 283 studies, 47 open.

Status

Completed
91
Status unknown
30
Recruiting
19
Not yet recruiting
15
Terminated
6
Active, not recruiting
4

Phase

Phase 2
52
Phase 3
28
Phase 4
19
Phase 1
16
Early Phase 1
5

Where

United States
59
Egypt
30
Pakistan
12
China
8
France
4
Netherlands
3

Who develops what

Add Warts to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 2 companies, 4 with this as their studies’ main aim; 3 with a live phase 3 study; 4 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.VP-102 · Verrica Pharmaceuticals Inc. · Phase 3 main aimNCT07246590 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) — primary endpoint: Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit. · 302 enrolled
  • Apr 2027 est.VP-102 · Verrica Pharmaceuticals Inc. · Phase 2 main aimNCT07881952 Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) — primary endpoint: Proportion of subjects exhibiting systemic exposure to YCANTH (VP-102) · 30 enrolled
  • May 2027 est.VP-102, TO-208 · Verrica Pharmaceuticals Inc. · Phase 3 main aimNCT07637734 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) — primary endpoint: Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit. · 300 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Warts studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

18studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 19 Warts studies recruiting now, 10 (53%) set no upper age limit and 9 (47%) stop at 75 or younger. 12 (63%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (5%) take healthy volunteers.

Recruiting studies that take each age, of 19
AgeWomenMen
109 (47%)9 (47%)
1819 (100%)19 (100%)
3017 (89%)17 (89%)
4017 (89%)17 (89%)
5017 (89%)17 (89%)
6514 (74%)14 (74%)
7510 (53%)10 (53%)
8510 (53%)10 (53%)

Across all 172 studies, recruiting or not: 41% stop at 75 or younger and 35% at 65; 49% take children; 2% are for women only and 1% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Warts studies take

Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 213 mo7–23 · 18 studies——
Interventional, no phase10 mo6–31 · 29 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 172. Browse all 172 → or search them.